---
title: "Publications"
permalink: /publication/
author_profile: true
---

{% include base_path %}


<H3>Publications</H3>

Lewis C, Boardman F, Buchanan J, Clark S, Gilchrist K, Hardelid P, Hunter A, Jones J, Leeson-Beevers K, Stafford-Smith B, Vindrola-Padros C, <b>Vu M</b>,  Wu WH, Zylbersztejn Hill M. <a href="https://www.medrxiv.org/content/10.1101/2024.05.14.24307295v1">Exploring the feasibility, acceptability and impact of genomic newborn screening for rare diseases in England: A study protocol for the Generation Study - Process and Impact Evaluation</a>. <i>medRxiv</i> 2024.

<b>Vu M</b>, Degeling K, Westerman D, IJzerman M. <a href="https://doi.org/10.1016/j.jcpo.2024.100501">Scenario analysis and multi criteria decision analysis to explore alternative reimbursement pathways for whole genome sequencing for blood cancer patients</a>. <i>Journal of Cancer Policy</i> 2024;41:100501.	

<b>Vu M</b>, Degeling K, Ryland LG, Hofman O, Ng AP, Westerman D, IJzerman M. <a href="https://doi.org/10.1016/j.jmoldx.2024.04.006">Economic impact of whole genome sequencing and whole transcriptome sequencing versus routine diagnostic molecular testing to stratify patients with B-cell acute lymphoblastic leukemia</a>. <i>The Journal of Molecular Diagnostics</i> 2024;26(8):673-684.

<b>Vu M</b>, Degeling K, Thompson ER, Westerman D, IJzerman M. <a href="https://doi.org/10.1007/s40258-023-00826-4">Cost effectiveness of molecular diagnostic testing algorithms for the treatment selection of frontline ibrutinib for patients with chronic lymphocytic leukemia in Australia</a>. <i>Applied Health Economics and Health Policy</i> 2024;22(1):107-122.

Fagery M, Khorshidi HA, Wong SQ, <b>Vu M</b>, IJzerman M. <a href="https://doi.org/10.1007/s40273-023-01292-5">Health economic evidence and modeling challenges for liquid biopsy assays in cancer management: a systematic literature review</a>. <i>Pharmacoeconomics</i> 2023;41(10):1229-1248.

<b>Vu M</b>, Degeling K, Thompson ER, Blombery P, Westerman D, IJzerman M. <a href="https://doi.org/10.1111/ejh.13755">Health economic evidence for the use of molecular biomarker tests in hematological malignancies: a systematic review</a>. <i>European Journal of Hematology</i> 2022;108(6):469-485.

<b>Vu M</b>, Carvalho N, Buchbinder R, Clarke PM, Tran-Duy A. <a href="https://doi.org/10.3899/jrheum.200231">Impact of comorbid conditions on health care expenditure and work-related outcomes in patients with rheumatoid arthritis</a>. <i>The Journal of Rheumatology</i> 2021;48(8):1221-1229.

<b>Vu M</b>, Degeling K, Martyn M, Lynch E, Chong B, Gaff C, IJzerman M. <a href="https://doi.org/10.1038/s41436-020-01030-8">Evaluating the resource implications of different service delivery models for offering additional genomic findings</a>. <i> Genetics in Medicine </i> 2020;23(4):606-613.

Degeling K, <b>Vu M</b>, Koffijberg H, Wong H-L, Koopman M, Gibbs P, IJzerman M. <a href="https://doi.org/10.1007/s40273-020-00908-4.">Health economic models for metastatic colorectal cancer: a methodological review</a>. <i>PharmacoEconomics</i> 2020;38(7):683-713.

<H3>Publications in progress</H3>

<H3>Presentations</H3>

<H3>Organised sessions at conferences</H3>

<H3>Poster presentations</H3>

<b>Vu M</b>, Degeling K, Thompson ER, Blombery P, Westerman D, IJzerman M. Cost-effectiveness of TP53 and IGHV biomarker testing prior to first-line treatment with novel agents for chronic lymphocytic leukemia. <i>ISPOR Europe 2022, Vienna, Austria.</i>

Ryland GL, Bajel A, Dickinson M, Ekert PG, Hofmann O, IJzerman M, Ng AP, Oshlack A, Schmidt B, Tiong IS, <b>Vu M</b>, Westerman DA, Grimmond S, Blombery P. Diagnostic utility of multimodal genomic profiling for molecular classification and MRD assessment in adult B-cell acute lymphoblastic leukemia. <i>2021 ASH Annual Meeting, Virtual.</i>

Degeling K, <b>Vu M</b>, Koffijberg H, Wong H-L, Koopman M, Gibbs P, IJzerman M. Clinical implications of assumptions in cost-effectiveness analyses of systemic therapies for metastatic colorectal cancer. <i>ASCO 2020, Virtual.</i>

<b>Vu M</b>, Carvalho N, Buchbinder R, McColl G, Clarke PM, Tran-Duy A. Impact of comorbid conditions on health care expenditure and work-related outcomes in patients with rheumatoid arthritis: a retrospective analysis using the Medical Expenditure Panel Survey in the period 2006-2015. <i>ISPOR 2019, New Orleans, USA.</i>

<H3>Papers discussed by others at conferences</H3>


